Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corporation - Common Stock
(NQ:
ABUS
)
4.805
-0.055 (-1.13%)
Streaming Delayed Price
Updated: 12:48 PM EDT, Sep 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arbutus Biopharma Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
↗
April 04, 2024
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
Via
Benzinga
Topics
Intellectual Property
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 04, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
↗
April 03, 2024
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.
Via
Benzinga
Topics
Intellectual Property
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
↗
May 04, 2023
Via
Benzinga
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
↗
October 05, 2023
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
September 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
September 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
August 03, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 20, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
July 12, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Appoints Two New Executives
July 10, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
June 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies Healthcare Conference
May 31, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at JMP Securities Life Sciences Conference
May 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
